

Press release 2011-09-28



C-RAD announces collaboration on the development motion management solutions for radiation therapy

C-RAD with its four fully owned subsidiaries are all active in the field of therapy. C-RAD will in cooperation with Swedish Cancer Institute in Seattle, Washington participate in the development of motion management solutions based on the new C-RAD Catalyst system.

For tumors impacted by respiratory motion, normal tissue toxicities limit the ability of radiation oncologists to deliver curative doses of radiation. By employing advanced motion management techniques, it is possible to deliver radiation in a more precise manner and achieve improved clinical outcomes. A key focus of the agreement will be development, testing, and clinical implementation of C-RAD surface mapping solutions as a tool for initial patient set up and real-time patient monitoring. A clinical protocol will be developed to collect and document the impact on clinical efficiency. Swedish Health Services will interface the C-Rad Catalyst system with its linear accelerators to provide gated treatments. The C-RAD Catalyst uses next generation optical surface scanning and re-projection hardware to continuously track each patient's surface throughout the set-up and delivery process. Radiation oncologist Vivek Mehta, M.D., who is director of Swedish Cancer Institute's Center for Advanced Targeted Radiotherapy said, "We believe this collaboration will result in the most advanced beam-gating solutions on the market and will allow us to achieve unprecedented dose conformity in the treatment of tumors in the lung, liver and pancreas."

Erik Hedlund, CEO, C-RAD AB:

"C-RAD received its largest order ever to deliver six Sentinel laser scanning systems to Swedish Cancer Institute in Seattle, USA. Two of the systems have been installed and are in clinical use.

C-RAD is much honored to have been selected as a partner to Swedish Cancer Institute to develop a new, advanced solution for gated treatments and motion management in radiation therapy."

For further information:

Erik Hedlund, CEO C-RAD AB, Phone +46 (0)18 66 69 31, E-mail erik.hedlund@c-rad.se

About C-RAD AB

C-RAD develops new and innovative solutions for the use in advanced radiation therapy. The company group of C-RAD offers products and solutions for patient positioning, tumor localization and radiation treatment systems. End users are radiation therapy clinics worldwide. All product development is conducted in four fully owned subsidiaries; C-RAD Positioning AB, C-RAD Imaging AB, C-RAD Innovation AB and C-RAD Incorporated. The headquarter of the group is located in Uppsala, Sweden. Numbers of employees are currently 20 people. The activities at C-RAD AB originate from research and development at the Karolinska Institutet in Solna. Sales of the company's first product, the C-RAD Sentinel™, started in 2007. Cooperation agreements have been signed with the Swedish company Elekta and the Belgian company IBA. C-RAD is represented by distributors specialized in radiation therapy on major markets. C-RAD AB is listed at Nasdaq Omx First North Premier.

About Swedish Cancer Institute

Based in Seattle, Swedish Cancer Institute (SCI) opened in 1932 as the first dedicated cancer treatment center west of the Mississippi River. Over the last 79 years, it has grown into the largest, most comprehensive cancer care program in the Pacific Northwest, caring for more people with more types of cancer than any other provider in the region. The Institute has a presence on all five of Swedish's hospital campuses – First Hill, Cherry Hill, Ballard, Edmonds and Issaquah – as well as in east King County and at Highline Medical Center in Burien. A true multidisciplinary institute, SCI offers a wide range of advanced cancer-treatment options in chemotherapy, radiation therapy and surgery – backed by extensive diagnostic capabilities, patient education and support-group services. The Center for Advanced Targeted Radiotherapy encompasses SCI's comprehensive and complementary array of advanced and emerging radiation delivery tools available to patients for both approved therapies and clinical research efforts. For more information, visit www.swedish.org/cancer.